Publisher middleman DeepDyve has launched a five-minute “freemium” service that CEO William Park says saves researchers money, and prevents the hassle of buying off-target research. Publishers such as Wiley support the service through cross-promotions on their websites.
Pradaxa dominates doc poll of most effective journal ads
The most effective journal ads of the year included executions for Pradaxa, Humira and Conceptus’ Essure Procedure, according to the Doctors’ Choice Study.
Medscape founder Peter Frishauf, advertising metrics pioneer David Labson and Dorothy Philips, Ph.D., who blazed a trail for women in medical advertising, are MAHF’s newest inductees.
New ad model fosters pharma’s leap to digital, publisher finds
Well before the FDA revoked Avastin’s approval in breast cancer, Roche’s Genentech unit deeply cut the professional media plan for the drug, the company said.
Majority of pharma journal ads not FDA-compliant: study
Four out of five ads analyzed in a study of physician-directed pharmaceutical advertising would definitely not pass FDA muster, or might have trouble doing so, said researchers. Their findings may have implications for the FDA, DDMAC and the “Bad Ad” program.
Ad for platelet-inhibition test pushes envelope, cardiologist asserts
Is a medical journal ad for platelet-inhibition testing backed up by evidence that treatment guided by such testing can reduce the risk of clot formation?